Central India Chronicle

Diverticulitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Warner Chilcott, Shire, Dr. Falk Pharma GmbH, Pfizer, SOFAR S.p.A., Deltex

 Breaking News
  • No posts were found

Diverticulitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Warner Chilcott, Shire, Dr. Falk Pharma GmbH, Pfizer, SOFAR S.p.A., Deltex

September 16
06:13 2023
Diverticulitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Warner Chilcott, Shire, Dr. Falk Pharma GmbH, Pfizer, SOFAR S.p.A., Deltex
Diverticulitis Market

DelveInsight’s “Diverticulitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diverticulitis, historical and forecasted epidemiology as well as the Diverticulitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Diverticulitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diverticulitis Market Forecast

 

Some of the key facts of the Diverticulitis Market Report: 

  • The Diverticulitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Diverticulosis prevalence has been reported to vary with age, from less than 20% at age 40 to 60% at age 60, according to Ghoulan et al. (2019). Diverticulitis is more common than it used to be, affecting 180/100,000 people annually, according to estimates
  • Diverticular illness is more common as people age (>65% in individuals >85 years). Diverticulitis patients tend to be older than 50; the average age at presentation seems to be around 60. Diverticulitis is, however, becoming more common in younger people
  • Key Diverticulitis Companies: Warner Chilcott, Shire, Dr. Falk Pharma GmbH, Pfizer, SOFAR S.p.A., Deltex Medical, Inc., Emmaus Medical, Cosmo Pharmaceuticals, and others
  • Key Diverticulitis Therapies: Mesalamine, SPD476, Rifamycin SV-MMX, Tigecycline, Mesalamine, Hextend, Endari, Aemcolo, and others
  • The Diverticulitis epidemiology based on gender analyzed that among people ages 50 and older, women are more likely than men to develop diverticulitis
  • The Diverticulitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diverticulitis pipeline products will significantly revolutionize the Diverticulitis market dynamics.

 

Diverticulitis Overview

A digestive disorder called diverticulitis affects the large intestine (bowel). Diverticulosis is a disorder that develops when tiny sacs or pouches form and push through openings in the colon’s wall. Diverticulitis develops when one or more of the pouches in the colon’s wall become inflamed while the patient has diverticulosis.

 

Get a Free sample for the Diverticulitis Market Report 

https://www.delveinsight.com/report-store/diverticulitis-market

 

Diverticulitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Diverticulitis Epidemiology Segmentation:

The Diverticulitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Diverticulitis
  • Prevalent Cases of Diverticulitis by severity
  • Gender-specific Prevalence of Diverticulitis
  • Diagnosed Cases of Episodic and Chronic Diverticulitis

 

Download the report to understand which factors are driving Diverticulitis epidemiology trends @ Diverticulitis Epidemiology Forecast

 

Diverticulitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diverticulitis market or expected to get launched during the study period. The analysis covers Diverticulitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diverticulitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Diverticulitis Therapies and Key Companies

  • Mesalamine: Warner Chilcott
  • SPD476: Shire
  • Rifamycin SV-MMX: Dr. Falk Pharma GmbH
  • Tigecycline: Pfizer
  • Mesalamine: SOFAR S.p.A.
  • Hextend: Deltex Medical, Inc.
  • Endari: Emmaus Medical
  • Aemcolo: Cosmo Pharmaceuticals

 

Diverticulitis Market Drivers

  • Increased obesity rates are anticipated to drive market expansion. Additionally, the market expansion for diverticulitis is being aided by the rising cigarette smoking population
  • Diverticulitis market demand is anticipated to be driven by continuing clinical trials on rare illnesses and a growth in demand for medications to treat the disease

 

Discover more about therapies set to grab major Diverticulitis market share @Diverticulitis Treatment Market

 

Scope of the Diverticulitis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Diverticulitis Companies: Warner Chilcott, Shire, Dr. Falk Pharma GmbH, Pfizer, SOFAR S.p.A., Deltex Medical, Inc., Emmaus Medical, Cosmo Pharmaceuticals, and others
  • Key Diverticulitis Therapies: Mesalamine, SPD476, Rifamycin SV-MMX, Tigecycline, Mesalamine, Hextend, Endari, Aemcolo, and others
  • Diverticulitis Therapeutic Assessment: Diverticulitis current marketed and Diverticulitis emerging therapies
  • Diverticulitis Market Dynamics: Diverticulitis market drivers and Diverticulitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Diverticulitis Unmet Needs, KOL’s views, Analyst’s views, Diverticulitis Market Access and Reimbursement 

 

To know more about Diverticulitis companies working in the treatment market, visit @ Diverticulitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Diverticulitis Market Report Introduction

2. Executive Summary for Diverticulitis

3. SWOT analysis of Diverticulitis

4. Diverticulitis Patient Share (%) Overview at a Glance

5. Diverticulitis Market Overview at a Glance

6. Diverticulitis Disease Background and Overview

7. Diverticulitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Diverticulitis 

9. Diverticulitis Current Treatment and Medical Practices

10. Diverticulitis Unmet Needs

11. Diverticulitis Emerging Therapies

12. Diverticulitis Market Outlook

13. Country-Wise Diverticulitis Market Analysis (2019–2032)

14. Diverticulitis Market Access and Reimbursement of Therapies

15. Diverticulitis Market Drivers

16. Diverticulitis Market Barriers

17.  Diverticulitis Appendix

18. Diverticulitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/rhino-conjunctivitis-market